MNKD vs URGN: stock comparison and AI forecast
Mannkind Corp (MNKD) and Urogen Pharma Ltd. (URGN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
MNKD Mannkind Corp
- Price
- $3.90 +9.9% · 6M
- Market Cap
- $1.25B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
URGN Urogen Pharma Ltd.
- Price
- $25.73 -3.2% · 6M
- Market Cap
- $1.26B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- MNKD and URGN have similar market capitalizations ($1.25B and $1.26B).
- Over the last six months MNKD returned +9.9% and URGN -3.2%.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | MNKD | URGN |
|---|---|---|
| Market Cap | $1.25B | $1.26B |
| EPS | $-0.08 | – |
| Revenue/Share | $1.29 | $5.12 |
| FCF/Share | $-0.24 | $-2.70 |
Profitability & Margins
| Metric | MNKD | URGN |
|---|---|---|
| ROA | – | -24.2% |
| ROIC | -1.9% | -15.6% |
| Gross Margin | 88.6% | 92.1% |
| Operating Margin | -2.9% | -12.4% |
| Net Margin | – | -26.3% |
| EBT Margin | -19.3% | -25.6% |
| Tax Rate | 6.0% | -2.5% |
Financial Health
| Metric | MNKD | URGN |
|---|---|---|
| Current Ratio | 2.22x | 3.40x |
| Quick Ratio | 1.77x | 3.06x |
| Interest Coverage | -0.1x | -18.7x |
| Working Capital | $132M | $178M |
Cash Flow
| Metric | MNKD | URGN |
|---|---|---|
| Operating Cash Flow | -$66M | -$132M |
| Free Cash Flow | -$78M | -$132M |
| Capital Spending | -$12M | -$200K |
| OCF Growth YoY | -235.6% | – |
| FCF Growth YoY | -280.7% | – |
| FCF/Sales | -19.0% | -52.8% |
| CapEx/Sales | 2.9% | 0.1% |
Operational Efficiency
| Metric | MNKD | URGN |
|---|---|---|
| Asset Turnover | 0.57x | 0.92x |
| Receivables Turnover | 10.1x | 2.1x |
| Inventory Turnover | 1.0x | 0.8x |
| Fixed Assets Turnover | 4.8x | 425.6x |
| Days Sales Outstanding | 36 days | 171 days |
| Days Inventory | 376 days | 466 days |
| Payables Period | 112 days | 320 days |
| Cash Conversion Cycle | 301 days | 317 days |
Income Statement
| Metric | MNKD | URGN |
|---|---|---|
| Total Revenue | $413M | $250M |
| Operating Income | -$12M | -$31M |
| Net Income | – | -$66M |
| R&D Expense | $77M | $73M |
| SG&A Expense | $232M | $186M |
| Cost of Goods Sold | $47M | $20M |
Dividend & Shareholder Information
| Metric | MNKD | URGN |
|---|---|---|
| Shares Outstanding | 322M | 49M |
| EPS Growth | -188.9% | – |
MNKD vs URGN: stock comparison and AI forecast
Which is bigger, MNKD or URGN?
MNKD and URGN have similar market capitalizations ($1.25B and $1.26B).
Which stock performed better over the last six months, MNKD or URGN?
Over the last six months MNKD returned +9.9% and URGN -3.2%.
Which one does Intratio's AI model rank higher, MNKD or URGN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.